Kancera AB’s fractalkine blockers have the potential to stop cancer cells acquiring resistance to chemotherapy and so offer potential to improve treatment for some advanced cancers, the Swedish biotech’s CEO tells Scrip.

Ex-Novartis executive and co-founder of investment bank MM Dillon & Co shares insights around where healthcare unicorns can be found and some core criteria to build such firms.

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.

As vaccine makers tackle SARS-CoV-2 variants, WHO’s Chief Scientist feels it’s important to continue immunization programs with existing vaccines. Meanwhile, the rollouts mean the safety and efficacy landscape is set to change, said participants at a recent meet